# Korro Bio

**Canonical:** https://apis.io/providers/korro-bio/  
**Website:** https://korrobio.com/  
**APIs profiled:** 0

Korro Bio, Inc. (Nasdaq: KRRO) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company developing a new class of genetic medicines based on programmable RNA editing. Its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform pairs data-driven oligonucleotide design and machine-learning optimization with linker chemistry and tissue-directed delivery to recruit the body's own ADAR enzymes and make a precise, transient single-base edit to a native mRNA transcript — editing RNA rather than DNA so the change is tunable and reversible. The company was created and incubated by Atlas Venture with New Enterprise Associates in October 2019, raised a $91.5M Series A and a $116M Series B, and became public in 2023 through a merger with Frequency Therapeutics alongside a $117M private placement. Its pipeline targets liver and central nervous system indications and includes KRRO-110 (the REWRITE Phase 1/2a study in alpha-1 antitrypsin deficiency), KRRO-111 and KRRO-121, which holds EMA orphan drug designation for urea cycle disorders. Korro Bio sells therapeutics, not software: it operates no developer program, publishes no API, SDK or machine-readable specification, and maintains no public source-code organization.

## Kin Score — 8.7 / 100 (minimal)

Scored 2026-08-25 under rubric 0.14.0. Trend: flat (+0.0 from 8.7).

| Facet | Score |
|---|---|
| Discoverability | 46.3 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## Security (1)

- **Korro Bio Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, RNA Editing, Genetic Medicine, Drug Discovery, Life Sciences, Clinical Trials, Rare Disease, Research

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/korro-bio/). Scores are computed from the provider's own public artifacts under a published rubric.